Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1997;5(5):319–325. doi: 10.1155/S1064744997000562

Ampicillin/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease

Joseph G Jemsek 1,2,✉, Frank Harrison 1
PMCID: PMC2364580  PMID: 18476179

Abstract

Objective: The safety and efficacy of ampicillin plus sulbactam were compared with those of cefoxitin in the treatment of women with pelvic inflammatory disease (PID).

Methods: This single-site, randomized, prospective, third-party-blinded, comparative, parallel-treatment study enrolled 93 women with a diagnosis of PID. Patients were treated with either ampicillin/sulbactam (2 g/1 g, administered intravenously [IV], every 6 h) or cefoxitin (2 g, administered IV, every 6 h) for a minimum of 12 doses. Patients with cultures positive for Chlamydia trachomatis also received concurrent oral or IV doxycycline (100 mg twice daily). Patients with cultures negative for C. trachomatis received prophylactic oral doxycycline (100 mg twice daily) for 10–14 days after treatment with either ampicillin/sulbactam or cefoxitin was completed.

Results: Ninety-three patients were entered in the study: 47 in the ampicillin/sulbactam arm and 46 in the cefoxitin arm. All 93 patients were evaluable for safety; 61 (66%) were evaluable for efficacy. Demographic characteristics were similar for the groups. Of the 27 evaluable ampicillin/sulbactam-treated patients, 67% experienced clinical cure, 30% improved, and 4% failed treatment. Respective values for the 34 cefoxitin-treated patients were 68%, 24%, and 9% (P = 0.67). Pathogens were eradicated in 70% of the women given ampicillin/sulbactam vs. 56% of those who received cefoxitin (P = 0.64).

Conclusions: Overall, ampicillin/sulbactam demonstrated clinical and bacteriologic efficacy at least equivalent to that of cefoxitin in the treatment of women with acute PID. The use of ampicillin/sulbactam for this indication may avoid the complex dosing regimens associated with other treatments.

Full Text

The Full Text of this article is available as a PDF (555.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson J. M., Nahata M. C. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination. Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):534–541. doi: 10.1177/106002808802200702. [DOI] [PubMed] [Google Scholar]
  2. Bowie W. R., Alexander E. R., Holmes K. K. Eradication of Chlamydia trachomatis from the urethras of men with nongonococcal urethritis by treatment with amoxicillin. Sex Transm Dis. 1981 Apr-Jun;8(2):79–81. doi: 10.1097/00007435-198104000-00010. [DOI] [PubMed] [Google Scholar]
  3. Centers for Disease Control (CDC) Sexually transmitted diseases treatment guidelines 1982. MMWR Morb Mortal Wkly Rep. 1982 Aug 20;31 (Suppl 2):33S–60S. [PubMed] [Google Scholar]
  4. Crombleholme W. R., Ohm-Smith M., Robbie M. O., DeKay V., Sweet R. L. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol. 1987 Feb;156(2):507–512. doi: 10.1016/0002-9378(87)90321-8. [DOI] [PubMed] [Google Scholar]
  5. Crombleholme W. R., Schachter J., Grossman M., Landers D. V., Sweet R. L. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol. 1990 May;75(5):752–756. [PubMed] [Google Scholar]
  6. Crombleholme W., Landers D., Ohm-Smith M., Robbie M. O., Hadley W. K., DeKay V., Dahrouge D., Sweet R. L. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs. 1986;31 (Suppl 2):11–13. doi: 10.2165/00003495-198600312-00003. [DOI] [PubMed] [Google Scholar]
  7. Dodson M. G. Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation. J Reprod Med. 1994 Apr;39(4):285–296. [PubMed] [Google Scholar]
  8. Dodson M. G. Optimum therapy for acute pelvic inflammatory disease. Drugs. 1990 Apr;39(4):511–522. doi: 10.2165/00003495-199039040-00004. [DOI] [PubMed] [Google Scholar]
  9. Gunning J. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease. Drugs. 1986;31 (Suppl 2):14–17. doi: 10.2165/00003495-198600312-00004. [DOI] [PubMed] [Google Scholar]
  10. Hemsell D. L., Heard M. C., Hemsell P. G., Nobles B. J. Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs. 1988;35 (Suppl 7):39–42. doi: 10.2165/00003495-198800357-00010. [DOI] [PubMed] [Google Scholar]
  11. Hemsell D. L., Wendel G. D., Hemsell P. G., Heard M. L., Nobles B. J. Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin. Infect Dis Obstet Gynecol. 1993;1(3):123–129. doi: 10.1155/S1064744993000286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. King L. A. Pelvic inflammatory disease. Its pathogenesis, diagnosis, and treatment. Postgrad Med. 1987 Mar;81(4):105-6, 109, 112-4. [PubMed] [Google Scholar]
  13. Kitrenos J. G., Rotella D. L., Nakasato S. Conversion of treatment from cefoxitin to ampicillin/sulbactam: experience in a university teaching hospital. Adv Ther. 1995 Jan-Feb;12(1):30–43. [PubMed] [Google Scholar]
  14. Kosseim M., Ronald A., Plummer F. A., D'Costa L., Brunham R. C. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam. Antimicrob Agents Chemother. 1991 Aug;35(8):1651–1656. doi: 10.1128/aac.35.8.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McGregor J. A., Crombleholme W. R., Newton E., Sweet R. L., Tuomala R., Gibbs R. S. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol. 1994 Jun;83(6):998–1004. doi: 10.1097/00006250-199406000-00020. [DOI] [PubMed] [Google Scholar]
  16. Murray P. R., Cantrell H. F., Lankford R. B. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group. Diagn Microbiol Infect Dis. 1994 Jun;19(2):111–120. doi: 10.1016/0732-8893(94)90121-x. [DOI] [PubMed] [Google Scholar]
  17. Peterson H. B., Galaid E. I., Cates W., Jr Pelvic inflammatory disease. Med Clin North Am. 1990 Nov;74(6):1603–1615. doi: 10.1016/s0025-7125(16)30497-7. [DOI] [PubMed] [Google Scholar]
  18. Rolfs R. T., Galaid E. I., Zaidi A. A. Pelvic inflammatory disease: trends in hospitalizations and office visits, 1979 through 1988. Am J Obstet Gynecol. 1992 Mar;166(3):983–990. doi: 10.1016/0002-9378(92)91377-m. [DOI] [PubMed] [Google Scholar]
  19. Safrin S., Schachter J., Dahrouge D., Sweet R. L. Long-term sequelae of acute pelvic inflammatory disease. A retrospective cohort study. Am J Obstet Gynecol. 1992 Apr;166(4):1300–1305. doi: 10.1016/s0002-9378(11)90626-7. [DOI] [PubMed] [Google Scholar]
  20. Soper D. E. Pelvic inflammatory disease. Infect Dis Clin North Am. 1994 Dec;8(4):821–840. [PubMed] [Google Scholar]
  21. Uri F. I., Sartawi S. A., Dajani Y. F., Masoud A. A., Barakat H. F. Amoxycillin/clavulanic acid (augmentin) compared with triple drug therapy for pelvic inflammatory disease. Int J Gynaecol Obstet. 1992 May;38(1):41–43. doi: 10.1016/0020-7292(92)90728-2. [DOI] [PubMed] [Google Scholar]
  22. Venezio F. R., O'Keefe J. P. Microbiologic considerations in the treatment of serious pelvic infections in women. J Reprod Med. 1988 Jan;33(1 Suppl):124–127. [PubMed] [Google Scholar]
  23. Walker C. K., Kahn J. G., Washington A. E., Peterson H. B., Sweet R. L. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis. 1993 Oct;168(4):969–978. doi: 10.1093/infdis/168.4.969. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES